A randomized, open-label, active-controlled, Phase II st

Project: Research project

Description

A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94- 9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line
StatusFinished
Effective start/end date7/1/1611/30/16

Funding

  • BAYER HEALTHCARE PHARMACEUTICALS

Fingerprint

anetumab ravtansine
mesothelin
vinorelbine
Malignant Mesothelioma